A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria
A Phase 2a, Randomized, Double-blind, Study of TAS5315 in Chronic Spontaneous Urticaria Patients With an Inadequate Response to H1-antihistamines
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Drug Information Center
- Phone Number: +81-3-3294-4527
- Email: th-tas5315_clinical@taiho.co.jp
Study Locations
-
-
-
Ehime, Japan
- A site selected by Taiho Pharmaceutical Co., Ltd.
-
Fukuoka, Japan
- A site selected by Taiho Pharmaceutical Co., Ltd.
-
Gunma, Japan
- A site selected by Taiho Pharmaceutical Co., Ltd.
-
Hiroshima, Japan
- A site selected by Taiho Pharmaceutical Co., Ltd.
-
Ishikawa, Japan
- A site selected by Taiho Pharmaceutical Co., Ltd.
-
Kagawa, Japan
- A site selected by Taiho Pharmaceutical Co., Ltd.
-
Kumamoto, Japan
- A site selected by Taiho Pharmaceutical Co., Ltd.
-
Obihiro, Japan
- A site selected by Taiho Pharmaceutical Co., Ltd.
-
Osaka, Japan
- A site selected by Taiho Pharmaceutical Co., Ltd.
-
Sapporo, Japan
- A site selected by Taiho Pharmaceutical Co., Ltd.
-
Tokyo, Japan
- A site selected by Taiho Pharmaceutical Co., Ltd.
-
Yokohama, Japan
- A site selected by Taiho Pharmaceutical Co., Ltd.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Aged 18 to 75 years
- Diagnosis of chronic spontaneous urticaria (CSU)
- Presence of itch and hives for at least 6 consecutive weeks prior to screening in spite of use of non-sedating H1-antihistamines for CSU
- UAS7 score ≥ 16 and HSS7 score ≥ 8 during 7 days prior to study entry
- In-clinic UAS ≥ 4 on study entry
- Willing and able to complete and Participate Daily for the duration of the study
Key Exclusion Criteria
- Diseases other than CSU with symptoms of urticaria or angioedema, including urticarial vasculitis, erythema multiforme, mastocytosis, or hereditary or acquired angioedema
- Atopic dermatitis, psoriasis, ichthyosis, or other skin disease associated with chronic itching
- Bleeding diathesis
- Uncontrolled hypertension disease states
- Treatment with omalizumab or other humanized anti-human IgE monoclonal antibody therapies used to treat CSU within 4 months prior to screening
- Nonresponse to omalizumab or other humanized anti-human IgE monoclonal antibody therapies
- Have been treated with other Bruton's Tyrosine Kinase inhibitors
- Pregnant or lactating women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
|
|
Experimental: TAS5315 Dose 1
|
Treatment period: oral administration for 12 weeks, QD
|
|
Experimental: TAS5315 Dose 2
|
Treatment period: oral administration for 12 weeks, QD
|
|
Experimental: TAS5315 Dose 3
|
Treatment period: oral administration for 12 weeks, QD
|
|
Experimental: AS5315 Dose 4
|
Treatment period: oral administration for 12 weeks, QD
|
|
Experimental: TAS5315 Dose 5
|
Treatment period: oral administration for 12 weeks, QD
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean change from baseline in weekly Urticaria Activity Score (UAS7) at week 12
Time Frame: Week 12
|
The UAS7 is the sum of the HSS7 score (weekly Hives Severity Sore) and the ISS7 score (weekly Itch Severity Score). The range of the UAS7 score is 0 - 42. (Zuberbier et al. 1995; Zuberbier et al., 2014) |
Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complete absence of hives and itch (UAS7=0)
Time Frame: Over time from week 1 to week 12
|
Over time from week 1 to week 12
|
|
|
Disease control (UAS7<=6)
Time Frame: Over time from week 1 to week 12
|
Over time from week 1 to week 12
|
|
|
Mean change from baseline in weekly Angioedema Activity Score (AAS7)
Time Frame: Over time from week 1 to week 12
|
The AAS is a validated tool to assess occurrence of episodes of angioedema.
The AAS7 is a weekly AAS score (AAS7).
Minimum and maximum possible AAS7 scores are 0-105.
|
Over time from week 1 to week 12
|
|
Mean change from baseline in Dermatology life quality index (DLQI)
Time Frame: Over time from week 1 to week 12
|
DLQI is a 10-item dermatology-specific quality of life (QoL) measure.
The range of the DLQI score is 0 - 30.
|
Over time from week 1 to week 12
|
|
Mean change from baseline in Urticaria control test (UCT)
Time Frame: Over time from week 1 to week 12
|
UCT is 4-item measure, which assesses symptoms, quality of life, treatment effectiveness.
The range of the UCT score is 0 - 16.
|
Over time from week 1 to week 12
|
|
Mean change from baseline in pharmacodynamics marker
Time Frame: Over time from week 1to week 12
|
Pharmacodynamics marker are IgG, IgM, IgA, IgE, CRP and D-dimer.
|
Over time from week 1to week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Taiho Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd.
Publications and helpful links
General Publications
- Zuberbier T, Chantraine-Hess S, Hartmann K, Czarnetzki BM. Pseudoallergen-free diet in the treatment of chronic urticaria. A prospective study. Acta Derm Venereol. 1995 Nov;75(6):484-7. doi: 10.2340/0001555575484487.
- Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, Ensina LF, Gimenez-Arnau A, Godse K, Goncalo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Abdul Latiff AH, Mathelier-Fusade P, Metz M, Nast A, Saini SS, Sanchez-Borges M, Schmid-Grendelmeier P, Simons FE, Staubach P, Sussman G, Toubi E, Vena GA, Wedi B, Zhu XJ, Maurer M; European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014 Jul;69(7):868-87. doi: 10.1111/all.12313. Epub 2014 Apr 30.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 10063040
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.